We entered the Latin American market in 2008 and initially established a presence in Brazil, Mexico and Venezuela. We have expanded our coverage in this region and now also have a presence in Colombia, Chile, Ecuador, Costa Rica, Peru and Argentina and offer a comprehensive product range that encompasses branded prescription and OTC products as well as infant nutritionals.Our Vallejo site in Mexico has the capability to manufacture infant nutritionals as well as pharmaceutical solids, semisolids and liquids.
Contribution to Group revenue
Revenue contribution - by therapeutic category
- The Spanish Latin American private pharmaceutical sector grew 8,9% to USD25,2 billion for the year to 30 June 2018 as per IMS.
- The Brazilian private pharmaceutical sector grew 5,4% and was valued by IMS at USD30,0 billion for the year to 30 June 2018.
Source: June 2018 IMS
Number of products launched:
IMS value of pipeline as at 30 June 2018 anticipated to be launched in:
0 – 2 years
3 – 5 years
Number of product recalls:
Average staff turnover:
Number of work-related fatalities:
Number of permanent employees:
|Revenue – R’billion||2018||2017 (CER)||% change|
|Total||4 231||3 991||6|
|Commercial Pharmaceuticals||2 929||2 577||14|
|Regional Brands||1 306||1 116||17|
|High Potency & Cytotoxics||790||803||(2)|
|Nutritionals||1 290||1 414||(9)|
|Manufacturing – FDF||12||–||100|
Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture